RXRX Valuation

Recursion Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.940

+0.16(3.347%)1D

Overview
Forecast
Valuation
Earnings

RXRX Relative Valuation

RXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RXRX is overvalued; if below, it's undervalued.

Historical Valuation

Recursion Pharmaceuticals Inc (RXRX) is now in the Fair zone, suggesting that its current forward PS ratio of 31.96 is considered Fairly compared with the five-year average of -7.71. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between 3.10 to 5.91 according to relative valuation methord.

Relative Value

Fair Zone

3.10-5.91

Current Price：5.17

Fair

-3.46

Trailing

Forward

-2.62

EV/EBITDA

Recursion Pharmaceuticals Inc. (RXRX) has a current EV/EBITDA of -2.62. The 5-year average EV/EBITDA is -6.65. The thresholds are as follows: Strongly Undervalued below -21.59, Undervalued between -21.59 and -14.12, Fairly Valued between 0.82 and -14.12, Overvalued between 0.82 and 8.29, and Strongly Overvalued above 8.29. The current Forward EV/EBITDA of -2.62 falls within the Historic Trend Line -Fairly Valued range.

-2.58

EV/EBIT

Recursion Pharmaceuticals Inc. (RXRX) has a current EV/EBIT of -2.58. The 5-year average EV/EBIT is -6.37. The thresholds are as follows: Strongly Undervalued below -20.10, Undervalued between -20.10 and -13.23, Fairly Valued between 0.49 and -13.23, Overvalued between 0.49 and 7.35, and Strongly Overvalued above 7.35. The current Forward EV/EBIT of -2.58 falls within the Historic Trend Line -Fairly Valued range.

30.01

Recursion Pharmaceuticals Inc. (RXRX) has a current PS of 30.01. The 5-year average PS is 88.59. The thresholds are as follows: Strongly Undervalued below -193.84, Undervalued between -193.84 and -52.62, Fairly Valued between 229.81 and -52.62, Overvalued between 229.81 and 371.03, and Strongly Overvalued above 371.03. The current Forward PS of 30.01 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Recursion Pharmaceuticals Inc. (RXRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -10.52. The thresholds are as follows: Strongly Undervalued below -26.33, Undervalued between -26.33 and -18.43, Fairly Valued between -2.61 and -18.43, Overvalued between -2.61 and 5.30, and Strongly Overvalued above 5.30. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-6.88

P/FCF

Recursion Pharmaceuticals Inc. (RXRX) has a current P/FCF of -6.88. The 5-year average P/FCF is -9.60. The thresholds are as follows: Strongly Undervalued below -23.02, Undervalued between -23.02 and -16.31, Fairly Valued between -2.89 and -16.31, Overvalued between -2.89 and 3.82, and Strongly Overvalued above 3.82. The current Forward P/FCF of -6.88 falls within the Historic Trend Line -Fairly Valued range.

Recursion Pharmaceuticals Inc (RXRX) has a current Price-to-Book (P/B) ratio of 2.25. Compared to its 3-year average P/B ratio of 3.78 , the current P/B ratio is approximately -40.62% higher. Relative to its 5-year average P/B ratio of 3.65, the current P/B ratio is about -38.52% higher. Recursion Pharmaceuticals Inc (RXRX) has a Forward Free Cash Flow (FCF) yield of approximately -17.80%. Compared to its 3-year average FCF yield of -14.76%, the current FCF yield is approximately 20.58% lower. Relative to its 5-year average FCF yield of -11.89% , the current FCF yield is about 49.78% lower.

2.33

P/B

Median3y

3.78

Median5y

3.65

-18.96

FCF Yield

Median3y

-14.76

Median5y

-11.89

Competitors Valuation Multiple

The average P/S ratio for RXRX's competitors is 6.68, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX) exhibits a P/S ratio of 30.01, which is 349.45% above the industry average. Given its robust revenue growth of 33.34%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RXRX.O

Recursion Pharmaceuticals Inc

Apogee Therapeutics Inc

Loss

2.28B

ARWR.O

Arrowhead Pharmaceuticals Inc

6.74

2.95B

Performance Decomposition

Market capitalization of RXRX decreased by 32.14% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 14.42M to 19.22M.

The secondary factor is the Margin Expansion, contributed 32.17%to the performance.

Overall, the performance of RXRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

33.34%

14.42M → 19.22M

Revenue Growth

32.17%

-676.56 → -894.23

Margin Expansion

-97.65%

-116.51 → -2.74

P/E Change

-32.14%